reason report
irish tax assess add risk lower pt reflect
bottom line follow file indic
irish author issu notic amend assess noa
assess tax liabil pertain sale tysabri
pharma updat valuat
reflect potenti liabil manag indic
strongli disagre assess appeal
believ uncertainti around whether may
abl win appeal long take get appeal
decis addit given magnitud potenti liabil
prior valuat lower
pt reflect potenti liabil maintain mp
appeal decis strongli believ
basi rule incorrect manag provid updat
relat rule irish offic revenu
commission irish revenu tax treatment
tysabri ip treat chargeabl gain subject tax
rate rather trade incom tax rate manag strongli
disput rule maintain file tax return correctli
point year histori trade ip without
disput irish revenu
see meaning uncertainti likelihood resolut
time horizon appeal process determin irish
revenu come audit find letter sent octob
two month end statut limit indic
claim highlight letter permit discuss
area disput irish revenu howev late novemb irish
revenu issu notic amend assess noa formal
rule irish revenu recent indic would
provid inform explain rule move
disclos indic file appeal strongli
disagre assess note reserv financi
account clear manag believ
strong posit see meaning uncertainti process
might play time horizon rule may come
ev/ebitda multipl incl
net debt total capit
gener
year price history/av daili volume mil
compani inform leerink partner llc research
revenu
pleas refer page import disclosur price chart analyst certif
rate market perform believ consum healthcar america chca like
continu grow low-singl digit consum healthcar chci also
grow low-singl digit growth potenti manag initi take time
play view howev unclear decis separ rx busi
immedi unlock valu enhanc growth consum healthcar segment
current still limit visibl medium-/long-term growth trajectori
busi final see signific uncertainti around irish revenu tax liabil rule
whether may abl win appeal long take get appeal
use ebitda appli weight averag ev/ebitda multipl
account potenti tax liabil arriv pt
limit rx-to-otc switch opportun and/or delay new rx over-the-counter product launch
could result share trade lower expect initi drive busi may
success anticip lead share perform better expect uncertainti
time and/or natur strateg review new ceo uncertainti time
eventu liabil amount relat tysabri ip sale
number except per share data
net debt ebitda ratio
number except per share data
number except per share data
long term growth
number except per share data
gsk product yokeb
number except per share data
gx bodi oil dermat
gx estrac estradiol vagin cream expect launch
gx finacea foam azela acid progress month stay expir juli
gx soolantra cream ivermectin rosacea ftf case progress
gx prolensa bromfenac ophthalm solut confidenti settlement assum compound patent tent approv
number except per share data
number except per share data
number except per share data
number except per share data
tysabri royalti stream fair valu
payrol relat tax
number except per share data
adjust reconcil ni net cash oper
tysabri toyalti stream chang fair valu
loss extinguish debt
impair equiti invest net
decreas increas work capit
proce royalti right
acquisit businesses/asset net cash acquir
proceed sale busi
settlement acquisition-rel foreign currenc deriv
purchas properti plant equip capital-expenditure
net invest
borrow repay revolv credit/oth net
premium earli debt retir
issuanc ordinari share
net financ
effect exchang rate chang cash/ cash equival
net chang equival
number except per share data
less debt
add
add tax liabil relat
share count
